Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  breast cancer in situ
Trial Status:  Closed
Sponsor of Trial:  NCI
Results 1-25 of 81 for your search:
Start Over
Diindolylmethane in Treating Patients With Breast Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Closed
Age: 19 and over
Sponsor: NCI, Other
Protocol IDs: 10-0366-04, NCI-2011-00710, R01CA149417-01A1, NCT01391689
Phase III Randomized Study of Venlafaxine for Hot Flashes in Women with Prior Breast Cancer (Summary Last Modified 01/2000)
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-979254, NCI-P98-0135
Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ
Phase: Phase III
Type: Treatment
Status: Closed
Age: 26 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-98-04, CDR0000067020, CAN-NCIC-MA26, CALGB-49801, RTOG-DEV-1026, NCI-2011-02038, MA26, NCT00003857
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069015, E-2193, NCI-P01-0194, ECOG-E2193, NCT00026286
Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069217, NCCTG-N99C7, NCI-P02-0204, NCT00030914
Phase III Randomized Study of Postoperative Radiotherapy Following Segmental Mastectomy and Axillary Dissection in Patients with Noninvasive Intraductal Adenocarcinoma of the Breast
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NSABP-B-17, CLB-8793, MAOP-1285, NCOG-NSABP-B-17
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NSABP B-39/RTOG 0413, NSABP-B-39, RTOG-0413, SWOG-NSABP-B-39, NCI-2009-00698, NCT00103181
Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NCCTG-N06C4, NCI-2012-02708, CDR0000530309, N06C4, NCT00438659
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00702, B-43, CDR0000615085, NSABP B-43, U10CA012027, U10CA180868, NCT00769379
S9630, Medroxyprogesterone in Treating Women With Breast Cancer
Phase: Phase III
Type: Prevention, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065314, CALGB-49901, S9630, U10CA037429, U10CA032102, SWOG-S9630, SWOG-9630, NCT00002920
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
Phase: Phase III
Type: Treatment
Status: Closed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: NSABP B-35, SWOG-NSABP-B-35, NCCTG-NSABP-B-35, ACOSOG-NSABP-B-35, NCT00053898
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG 1005, NCI-2011-02669, CDR0000700069, NCT01349322
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Phase: Phase II
Type: Natural history/Epidemiology
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065370, U10CA021115, E-5194, NCT00002934
Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer
Phase: Phase II
Type: Prevention
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: ID94-029, P30CA016672, MDA-ID-94029, NCI-P97-0113, CDR0000065829, NCT00003099
Raloxifene in Preventing Breast Cancer in Premenopausal Women
Phase: Phase II
Type: Prevention
Status: Completed
Age: 23 to 47
Sponsor: NCI
Protocol IDs: CDR0000066428, NCI-98-C-0123, MB-402, NCT00019500
Phase II Randomized Study of Exemestane and Raloxifene in Postmenopausal Women With a History of Stage 0 (Ductal Carcinoma in Situ), I, II, or III Breast Cancer Who Have No Clinical Evidence of Disease
Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-99017, NCI-G99-1662, NCT00004247
Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease
Phase: Phase II
Type: Supportive care
Status: Completed
Age: Postmenopausal (20 and over)
Sponsor: NCI, Other
Protocol IDs: CDR0000069219, U10CA076001, CALGB-79805, NCI-P02-0206, NCT00031720
Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: ICC4102, P30CA043703, CWRU-ICC-4102, NCT00054301
Phase II Randomized Study of Tamoxifen and Fenretinide for the Prevention of Breast Cancer
Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: CNR-IEO-007, U01-CA77188-01
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: 040044, 04-C-0044, NCT00073073
Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000365456, P30CA006927, 03026, FCCC-03026, NCT00084539
Letrozole in Preventing Breast Cancer in Postmenopausal Women
Phase: Phase II
Type: Prevention
Status: Completed
Age: 35 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000375585, DFCI-00024, UCLA-0210012-02, NCT00090857
Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 45 to 65
Sponsor: NCI, Other
Protocol IDs: CDR0000428460, P30CA016042, UCLA-0410033-01, NCT00112749
Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: J0365 CDR0000446285, P30CA006973, JHOC-J0365, JHOC-SKCCC-J0365, JHOC-IRB-03100706, NCT00244959
Start Over